Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20809633 | 0.83 | GPR88 (0.31) | — | |
| SCHEMBL11079192 | 0.83 | ALDH1A1 (0.42) | ALDH1A1KAT8SMN1; SMN2LMNA | |
| SCHEMBL1269651 | 0.78 | THRB (0.49) | ALDH1A1KAT8 | |
| SCHEMBL23135892 | 0.73 | ALDH1A1 (0.41) | ALDH1A1LMNA | |
| SCHEMBL7518065 | 0.72 | — | — | |
| SCHEMBL20809612 | 0.72 | USP2 (0.44) | ALDH1A1MEN1LMNAMAPTKMT2A | |
| SCHEMBL20809601 | 0.72 | HRH3 (0.54) | — | |
| SCHEMBL11216376 | 0.72 | MAOA (0.36) | MAOA | |
| SCHEMBL114275 | 0.72 | HCAR2 (0.54) | ALDH1A1NPC1SMN1; SMN2RAB9ALMNA | |
| SCHEMBL13546077 | 0.72 | CYP1A2 (0.40) | MAOAKAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046670-B2 | Piperazinyl norbenzomorphan compounds and methods for using the same | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-29 | — | — | US | disclosed |
| US-20190077789-A1 | PIPERAZINYL NORBENZOMORPHAN COMPOUNDS AND METHODS FOR USING THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077789-A1 | PIPERAZINYL NORBENZOMORPHAN COMPOUNDS AND METHODS FOR USING THE SAME | GAP43, NCDN, NLN | MAOA 2756/4885ALDH1A1 1985/4885KAT8 1299/4885 |
| US-11046670-B2 | Piperazinyl norbenzomorphan compounds and methods for using the same | GAP43, NCDN, NLN | MAOA 2756/4885ALDH1A1 1985/4885KAT8 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.